GeneDx Holdings Corp. (NASDAQ:WGS) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of GeneDx Holdings Corp. (NASDAQ:WGS) have been given an average rating of “Moderate Buy” by the six analysts that are covering the company, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $72.33.

Several analysts have recently commented on WGS shares. The Goldman Sachs Group increased their price target on shares of GeneDx from $70.00 to $80.00 and gave the company a “neutral” rating in a research report on Wednesday. Wells Fargo & Company increased their price target on shares of GeneDx from $34.00 to $75.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 30th. TD Cowen increased their price target on shares of GeneDx from $75.00 to $118.00 and gave the company a “buy” rating in a research report on Tuesday, January 7th. Finally, Craig Hallum raised their target price on shares of GeneDx from $70.00 to $95.00 and gave the stock a “buy” rating in a research report on Wednesday, October 30th.

Insider Buying and Selling at GeneDx

In other news, CEO Katherine Stueland sold 51,420 shares of the firm’s stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $94.48, for a total value of $4,858,161.60. Following the transaction, the chief executive officer now owns 1,720 shares of the company’s stock, valued at approximately $162,505.60. This trade represents a 96.76 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Kevin Feeley sold 1,137 shares of the firm’s stock in a transaction on Monday, December 9th. The shares were sold at an average price of $76.37, for a total transaction of $86,832.69. Following the completion of the transaction, the chief financial officer now directly owns 24,731 shares in the company, valued at approximately $1,888,706.47. This represents a 4.40 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 127,584 shares of company stock worth $11,336,520 in the last quarter. 27.30% of the stock is owned by insiders.

Hedge Funds Weigh In On GeneDx

A number of hedge funds have recently made changes to their positions in WGS. SG Americas Securities LLC purchased a new position in shares of GeneDx in the 3rd quarter valued at $198,000. CWM LLC purchased a new stake in GeneDx during the 3rd quarter worth $89,000. Raymond James & Associates purchased a new stake in GeneDx during the 3rd quarter worth $8,090,000. Precision Wealth Strategies LLC purchased a new stake in GeneDx during the 3rd quarter worth $364,000. Finally, Palumbo Wealth Management LLC purchased a new stake in GeneDx during the 3rd quarter worth $287,000. Hedge funds and other institutional investors own 61.72% of the company’s stock.

GeneDx Trading Down 5.7 %

Shares of GeneDx stock opened at $95.83 on Tuesday. GeneDx has a 12-month low of $6.79 and a 12-month high of $115.60. The company has a current ratio of 2.40, a quick ratio of 2.27 and a debt-to-equity ratio of 0.25. The stock has a market cap of $2.63 billion, a PE ratio of -48.89 and a beta of 2.01. The company has a 50-day moving average of $79.05 and a two-hundred day moving average of $63.12.

GeneDx (NASDAQ:WGS) last issued its earnings results on Tuesday, February 18th. The company reported $0.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.04 by $0.66. The company had revenue of $95.64 million during the quarter, compared to analysts’ expectations of $82.24 million. GeneDx had a negative net margin of 17.12% and a positive return on equity of 3.33%. On average, research analysts anticipate that GeneDx will post 0.97 EPS for the current fiscal year.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.